Quantitative Histological Analysis of SM22α (Transgelin) in an Adriamycin-Induced Focal Segmental Glomerulosclerosis Model

Xingzhi Wang a Minoru Sakatsume a Yuichi Sakamaki a Shigeru Inomata a
Tadashi Yamamoto b Ichiei Narita a

a Division of Clinical Nephrology and Rheumatology, and b Division of Structural Pathology, Institute of Nephrology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan

Key Words
SM22α · Transgelin · Focal segmental glomerulosclerosis · Adriamycin nephropathy · Podocyte · Interstitial cell · Tubulointerstitium

Abstract
Background/Aims: SM22α, transgelin, has been revealed to be specifically expressed in glomerular epithelial cells and interstitial cells, according to the nature of the renal injury. In this study, quantitative analyses of SM22α positivity were performed to investigate the pathological significance of its expression. Methods: Kidney samples of adriamycin nephropathy underwent immunohistochemistry with a newly established anti-SM22α monoclonal antibody. The SM22α positivity was quantified by an image analyzer. The correlation of the histological values with biochemical data was investigated statistically. Microstructural localization of SM22α was studied by immunoelectron microscopy. Results: SM22α was expressed along the dense basal microfilaments of degenerating podocytes, and diffusely in interstitial cells. Both the extent and intensity of SM22α expression in glomerular and tubulointerstitial area were correlated with the deterioration of renal function and the severity of proteinuria. Stepwise multiple linear regression analysis revealed that the extent of its positivity in glomerular or tubulointerstitial area was the determinant of the amount of proteinuria or the deterioration of creatinine clearance (Ccr), respectively. Inversely, the deterioration of Ccr was the most important predictor of SM22α expression. Conclusion: SM22α expression in podocytes and interstitial cells represented the severity of proteinuria and the deterioration of renal function. SM22α expression in renal tissues might be a hallmark of kidney diseases.

Introduction

SM22α (transgelin) was first identified as a 22-kDa protein in smooth muscles [1, 2]. It has variably been designated as p27 [3] or WS3–10 [3]. It is abundantly expressed in smooth muscle cells (SMCs) and is recognized as its differentiation marker [4, 5]. It is localized in the cytoskeletal apparatus [6] and is a member of calponin family [7, 8]. The function of SM22α has not yet been completely elucidated. SM22α-deficient mice normally develop and appear similar to control mice [9]. However, SM22α is downregulated in SMCs in atherosclerotic lesions, and its gene ablation in apoE-deficient mice results in the extension of atherosclerotic lesions and increases the number of proliferating SMCs in plaque, indicating...
that SM22α may be involved in controlling the phenotypic modulation of SMCs, from contractile to proliferative, in the sclerotic artery [10]. Its expression has also been detected in several epithelial cells [7, 11, 12]. Upon tissue injuries, SM22α is increasingly expressed in alveolar epithelial cells, and it may directly contribute to the lung fibrosis [13]. Moreover, SM22α acts to suppress expression of the matrix metalloproteinase-9 [14], which is involved in the tissue remodeling. Loss of its expression could be involved in the development of cancer, or SM22α could act as a tumor suppressor [7, 11, 12, 15]. Thus, both the functional and pathological significance of SM22α expression have recently attracted attention.

Focal segmental glomerulosclerosis (FSGS) is a severe renal disease showing massive proteinuria, focal segmental glomerular consolidation and, in many cases, progressively declining renal function accompanied with increasing tubulointerstitial fibrosis. Because the pathological feature of FSGS is a foot process effacement of the glomerular epithelial cells (podocytes) followed by glomerulosclerosis, FSGS is primarily considered to be a podocyte disease [16]. The adriamycin (ADR) nephropathy has been used widely as a rat experimental model of FSGS [17].

We have reported in previous studies [18, 19] that SM22α was inductively expressed in injured podocytes in the early phase of a rat anti-glomerular basement membrane nephritis model. In addition, SM22α was expressed in diverse models of glomerular and tubulointerstitial injury [20], including the 5/6 nephrectomy model, the renal ischemia-reperfusion model and puromycin aminonucleoside nephrosis. SM22α might be a phenotypic marker of the injured kidney cells and be expressed in specific sites according to the nature of the injury.

In those studies, we did not perform the quantitative histological analysis of SM22α expression, nor did we show how it correlated with the disease activity. In this present study we have investigated these undetermined issues to elucidate its pathological significance, using a rat FSGS model, ADR nephropathy, which showed both podocyte and tubulointerstitial injury and progressive renal dysfunction, using a newly established, highly specific anti-SM22α monoclonal antibody (mAb).

**Materials and Methods**

**ADR Nephropathy**

Adult male 7-week-old Wistar rats weighing between 150 and 250 g were purchased from Charles River Japan (Tokyo, Japan), and were randomly assigned into five groups: control group (n = 5), day 7 group (n = 5), day 14 group (n = 5), day 28 group (n = 4), and day 42 group (n = 5). ADR nephropathy was induced in ADR groups by a single caudal vein injection of 6 mg/kg ADR (adriamycin hydrochloride), which was purchased from Wako Pure Chemicals (Tokyo, Japan) dissolved in normal saline solution. The control group was injected the equivalent volume of normal saline solution. The groups of rats were sacrificed on days 7, 14, 28, 42 after the ADR injection, respectively. This study was approved by the Ethical Committee for Animal Research of Niigata University.

**Blood and Urine Biochemical Variables**

Blood samples were collected for measurement of blood urea nitrogen (BUN) and serum creatinine (Scr) at the time of sacrifice. 24-Hour urine samples were collected using metabolic cages for measurement of urinary protein (UP) (SRL, Tokyo, Japan) as described previously [21, 22].

**Recombinant Protein of the Rattus norvegicus SM22α**

The rat SM22α recombinant protein (rSM22α) was prepared as previously described [18]. Briefly, the pQE-30UA vector into which the in-frame 260 bp of rat SM22α cDNA corresponding to amino acids 85–170 prepared by PCR was ligated and transformed into *Escherichia coli* strain JM109 (Toyobo, Osaka, Japan). The production of 6× his positive recombinant SM22α was induced by isopropyl-β-D-thiogalactopyranoside in Lennox Broth medium and the cells were then lysed and centrifuged. The supernatant was subjected to affinity purification with QIAexpress Type IV kit (Qiagen, Tokyo, Japan).

**Production of mAb against rSM22α**

The mAb against rSM22α was raised by Medical & Biological Laboratories Co. Ltd (Nagano, Japan) [23, 24]. Briefly, BALB/c mice were immunized with rSM22α and complete Freund’s adjuvant (1:1). The lymph node cells were then removed from immunized mice and fused with P3U1 myeloma cells at a ratio of 5:1 by the polyethylene glycol-400 procedure. Hybridoma supernatants were screened by ELISA using the immunogen. After cloning the hybridomas, the mAbs were purified by protein G Sepharose column chromatography. Among the hybridomas, clone 75–7 was selected based on its ability to perform immunochemistry. Its isotype was determined as IgG1.

**Two-Dimensional Western Blot Analysis**

100 μg of proteins of lysate from normal Wistar rat aorta was loaded. The first dimension was carried out on a Zoom™ IPGRunner system (Invitrogen Corp.) using pH 3–10 gel strips. Strips were rehydrated at room temperature (RT) for 12 h in 12 μl of sample. Isoelectric focusing was performed at RT under the following conditions: 15 min at 175 V, 45 min at 175–2,000 V, and 30 min at 2,000 V. In order to eliminate disulfide bonds in the focused proteins prior to SDS-PAGE, IPG strips were incubated for 15 min in equilibration buffer which consisted of 9 ml 1X NuPage® LDS sample buffer and 1 ml of 10 mM DTT. The IPG strips were then soaked in alkylation buffer for an additional 15 min to alkylate the sulfhydryl groups. Alkylation buffer was produced by 125 mM iodoacetamide solved in 10 ml of 1X NuPage® LDS sample buffer. The strips were then embedded in 0.3% w/v agarose on top of Novex® 4–12% Bis-Tris Zoom® gels and the second dimension separation was carried out at RT at constant voltage of 200 V for 50 min. The protein was transferred to a PVDF membrane.
blocked with 10% powdered milk in TBST (20 mM Tris-HCl, pH 8.0, 0.5 M NaCl, 0.5% Tween 20), then incubated with anti-rSM22α mAb, 75–7, overnight at 4°C.

Peroxidase-conjugated goat anti-mouse IgG Ab (Dako) was used as the secondary Ab, and the immune complex was visualized using ECL (Western blotting detection reagents; Amersham). Normal mouse IgG1 was used as a control of the primary antibody.

Immunohistochemistry

The 5-μm sections were deparaffinized in xylene and ethanol, and rehydrated in water. The sections were then washed in PBST (0.05% Tween 20) for 5 min. Slides were incubated in endogenous peroxidase buffer (a mixture of 5 ml 3% H2O2 and 45 ml methanol) for 20 min at RT. The sections were then washed in PBST for 5 min. Before incubating the slides with anti-rSM22α mAb, 75–7, as the primary antibody for 2 h at RT, block slides with 3% BSA were done for 60 min. After washing the sections for 15 min with PBST, the slides were incubated with peroxidase-conjugated goat anti-mouse IgG (Dako, Carpinteria, Calif., USA) as the secondary antibody for 30 min at RT. They were then gently rinsed with distilled water for about 15 min. The immune complex was detected with 3,3-diaminobenzidine tetrahydrochloride (Dako), and counterstaining was performed with hematoxylin. Control sections were treated with mouse IgG1 as the primary antibody.

Evaluation of SM22α-Positive Staining

All sections were stained at the same laboratory by a researcher following exactly the same protocol of IHC using the same antibodies. Photos were also taken under precisely the same exposure time and shutter speed, to avoid any errors, using a Nikon Eclipse E-600 microscope (Tokyo, Japan) coupled to a Pro-Series High-Performance CCD camera. The SM22α staining was digitized using Image-pro Plus (Media Cybernetics, Silver Spring, Md., USA). Before detections of SM22α-positive staining, the integrated optical density (IOD) was calibrated and the glomerular area (GA) and tubulointerstitial area (TA) were selected arbitrarily. Then, in those selected areas, the SM22α-positive area (PA) was counted. The statistical data of PA in GA (PA/GA), IOD in GA (IOD/GA), PA in TA (PA/TA) and IOD in TA (IOD/TA) were obtained. All the values were determined by measuring three times each glomerulus and TA, which were randomly selected in five serial sections of a single kidney of rats (see fig. 5).

Statistical Analyses

All data are shown as mean ± SD. One-way factorial ANOVA with a Bonferroni-Dunn post-hoc test was applied for comparing values of the experimental groups. Pearson correlation coefficients were used to evaluate correlations between histological values and biochemical data. The stepwise multiple linear regression analysis was used to determine the histological values contributing to changes of biochemical data, and vice versa. Statistical analyses were performed using SPSS 12.0 Software (SPSS Inc., Chicago, Ill., USA). The difference was considered statistically significant at p < 0.05.

Results

Specificity of mAb against rSM22α, 75–7

To study the pathophysiological features of SM22α in renal diseases reproducibly, we established some stable hybridoma clones using the recombinant rat SM22α as an immunogen, which had also been employed for making the polyclonal Ab in our previous study. Among the clones, we picked up clone 75–7 because of its strong reactivity for immunohistochemistry. In order to check the specificity, we performed two-dimensional Western blot analysis using the rat aorta. As shown in figure 1, clone 75–7 recognized a single spot of 22 kDa protein at around pH 9.0, which is consistent with previously published data [25].

Immunohistochemistry of SM22α in Glomeruli of Rat ADR Nephropathy

As shown in figures 2 and 3, in control rats, SM22α was only detected in vessel walls. Seven days after ADR injection, SM22α was newly detected in glomeruli seg-
Fig. 2. Immunohistochemistry of SM22α in glomeruli of ADR nephropathy. The left column was stained with anti-rSM22α mAb (75–7), the middle column shows the negative controls which are incubated with nonspecific isotype-matched mouse IgG1, and the right column shows PAS staining. Serial sections were used for each staining. Orig. magnif. ×800.
**Fig. 3.** Immunohistochemistry of SM22α in the TA of ADR nephropathy. The left column was stained with anti-rSM22α mAb (75–7), the middle column shows the negative control tissues which are incubated with nonspecific isotype-matched mouse IgG1, and the right column shows PAS staining. Serial sections were used for each staining. Orig. magnif. ×800.
mentally in an epithelial pattern. After day 28 it became positive in interstitial cells, as well as glomerular cells. On day 42, when lesions of FSGS and interstitial fibrosis were apparent, SM22α was detected in the sclerotic lesions of glomeruli. The staining of TAs is shown in figure 3. After day 14, interstitial cells were positive for SM22α.

Immunoelectron Microscopy
To investigate SM22α expression in the cells in detail, we performed immunoelectron microscopy by immunogold technique. In control normal rats, SM22α was negative in glomerular epithelial cells (fig. 4a) or periglomerular interstitial area (fig. 4b). In rats on day 42 after ADR injection, podocytes became swollen and showed the foot process effacement in part. SM22α was preferentially expressed along the dense basal microfilaments of podocytes (fig. 4c). The interstitial cells (probably fibroblasts) around the glomeruli were also positive for SM22α (fig. 4d).

Quantitative Analysis of Sections Stained with Anti-rSM22α mAb (75–7) and Biochemical Parameters
In order to investigate the relationship between SM22α expression and parameters of urine and blood data, we first quantified the extent and intensity of SM22α expression by using Image-pro Plus software. SM22α-PA and IOD in glomerular or tubulointerstitial areas were measured. The data were divided by the values of selected GA or TA for standardization (fig. 5). The data of groups are shown in figure 6. Urine and blood biochemical data such as creatinine clearance (Ccr), Scr, BUN, the amount of proteinuria (UP) and the ratio of UP to the concentration of urinary creatinine (UP/Ucr) of groups are shown in figure 7.

Correlation analysis (fig. 8) showed that the histological parameters of SM22α expression, such as PA/GA, IOD/GA, PA/TA and IOD/TA, were significantly associated with biochemical data presenting renal function including Ccr, BUN and Scr, and the severity of proteinuria including UP and UP/Ucr. Especially, as for renal function, Ccr was most strongly associated with PA/TA (R² = 0.8460, p < 0.0001). As for severity of proteinuria, UP/Ucr was moderately associated with PA/GA (R² = 0.4348, p = 0.0029). A stepwise multiple linear regression incorporating all the histological parameters of SM22α expression showed that PA/TA or PA/GA were predictors of Ccr or UP/Ucr, respectively (table 1a). Inversely, the deterioration of Ccr was the most important predictor of all parameters of SM22α expression (table 1b).
Fig. 5. Quantification of SM22α-positive staining. The immunohistochemical sections were studied by using Image-Pro Plus software on SM22α immunostained sections to quantitate the area of positive staining (PA), the whole area of the selected glomerulus (GA), the IOD of PA and the whole area of the selected TA. The positive staining was identified in the statistical red color, and calculated in green numbers. The data are shown in the forms. The values of PA/GA, IOD/GA, PA/TA and IOD/TA were used for statistical analyses.

Table 1. Stepwise multiple linear regression models

<table>
<thead>
<tr>
<th>Dependent variable and model</th>
<th>Independent variable</th>
<th>Unstandardized β-coefficient</th>
<th>Standardized β-coefficient</th>
<th>$R^2$</th>
<th>F</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>a Regression model including PA/GA, IOD/GA, PA/TA, IOD/TA</td>
<td>Ccr One step PA/TA</td>
<td>-13.984</td>
<td>-0.92</td>
<td>0.836</td>
<td>87.897</td>
<td>0.0001</td>
</tr>
<tr>
<td></td>
<td>UP/Ucr One step PA/GA</td>
<td>0.486</td>
<td>0.659</td>
<td>0.399</td>
<td>12.31</td>
<td>0.003</td>
</tr>
<tr>
<td>b Regression model including Ccr, Scr, BUN, UP, UP/Ucr</td>
<td>PA/GA One step Ccr</td>
<td>-0.087</td>
<td>-0.883</td>
<td>0.765</td>
<td>56.356</td>
<td>0.0001</td>
</tr>
<tr>
<td></td>
<td>IOD/GA One step Ccr</td>
<td>-0.03</td>
<td>-0.859</td>
<td>0.722</td>
<td>45.134</td>
<td>0.0001</td>
</tr>
<tr>
<td></td>
<td>PA/TA One step Ccr</td>
<td>-0.06</td>
<td>-0.92</td>
<td>0.836</td>
<td>87.897</td>
<td>0.0001</td>
</tr>
<tr>
<td></td>
<td>IOD/TA One step Ccr</td>
<td>-0.019</td>
<td>-0.901</td>
<td>0.8</td>
<td>68.847</td>
<td>0.0001</td>
</tr>
</tbody>
</table>
Fig. 6. The extent and the intensity of SM22α-positive staining. The values of PA/GA, IOD/GA, PA/TA and IOD/TA of control and ADR-treated groups, calculated in figure 5, are shown. One-way factorial ANOVA with a Bonferroni-Dunn post-hoc test was applied for comparing values of the experimental groups (* p < 0.01).

Fig. 7. Biochemical data of blood and urine of ADR nephropathy. Biochemical data of blood and urine of control and ADR-treated groups are shown. One-way factorial ANOVA with a Bonferroni-Dunn post-hoc test was applied for comparing values of the experimental groups (* p < 0.01, ** p < 0.05).
Fig. 8. Pearson correlation matrix among variables of blood/urine biochemical data and SM22α expression. The correlation between blood/urine biochemical data and the histological parameters of control and ADR nephropathy rats was investigated. Scatter diagrams of bivariate correlations are shown as graphs with tables of results.
Discussion

In the present study, using a highly specific monoclonal anti-rat SM22α mAb (75–7), we quantified the extent and intensity of SM22α expression in a well-known model of FSGS, ADR nephropathy, which demonstrated damages of glomerular epithelial cells first, and tubulointerstitial cells later. In kidney diseases, in general, various kinds of histological damage, such as glomerular and tubulointerstitial disorders, are mixed together. Then, taken together with all data of stages of ADR nephropathy, we investigated the correlation between histological parameters of SM22α expression and biochemical data. Both the extent and intensity of SM22α expression in glomerular and TA were correlated with the deterioration of renal function and the severity of proteinuria. In order of importance, the extent of SM22α expression in tubulointerstitial area (PA/TA) was the predictor of the deterioration of renal function (Ccr), and that in the glomerular area (PA/GA) was the predictor of the severity of proteinuria (UP/Ucr). Thus, it seemed that SM22α expression in glomerular cells, mainly podocytes, reflected the dysfunction of those cells, resulting in proteinuria, and that its expression in interstitial cells represented the tubulointerstitial damage, which is a common appearance of kidney diseases presenting progressive renal dysfunction.

The immunostaining results using our mAb, 75–7, were basically identical to those obtained by anti-SM22α polyclonal Ab in our previous studies [18, 20], although disease models were different from each other. SM22α was detected in glomerular epithelial cells first, and also in tubulointerstitial cells later in this model. By immunohistology, as the results in our previous study [20], SM22α was positive in the basal microfilament layer of podocytes, which showed foot process effacement, and on the other hand, it was detected diffusely in the cytoplasm of tubulointerstitial cells. It seemed to be a universal phenomenon that SM22α was de novo expressed in specific sites, such as glomerular epithelial cells and tubulointerstitial cells, according to the nature of the injury.

The inducible expression of SM22α might imply the acquisition of contractile or degenerative properties by the kidney cells. Because SM22α is originally localized in the cytoskeleton of SMCs, the difference of its distribution between glomerular epithelial cells and tubulointerstitial cells might be derived from the anatomical relationship of the cells to surrounding extracellular matrices. The modified environment for the attachment of cells to extracellular matrices and tension generation might lead to the SM22α expression in accordance with the actin reorganization under the diseased conditions.

The functional consequence of SM22α expression in the glomerular cells, including injured podocytes, remains unclear. In podocytes, upon the glomerular injury, actin fibers might be reorganized and form dense microfilament bundles containing SM22α. The cytoskeletal changes in podocytes were precisely investigated in previous studies [26], reporting that the dense microfilament network appeared along the basal cell membrane of podocytes. The dense bundles contained α-actinin, which might serve as a cross-linker for the microfilaments and represent the contractile phenotypic change of podocytes upon glomerular injury. Because SM22α is known to be associated with actin stress fibers and stabilize actin gels in vitro [7], it might also work as a factor that promoted the reorganization of the actin cytoskeleton of podocytes and supported some functions of podocytes under the diseased condition induced by the cytotoxic reagent, ADR. In this present study it was revealed that SM22α expression in renal cells represented the severity of proteinuria and the deterioration of renal function. Its expression in podocytes might demonstrate the severity of cell damage, where it might work to maintain configuration of podocytes as a barrier for protein loss. Its expression in interstitial cells might reflect the tubulointerstitial disorder, which was an outcome of disease progression. In our study using the late phase of an anti-glomerular basement membrane glomerulonephritis model, when interstitial fibrosis was evident, SM22α was costained with αSMA (α-smooth muscle actin) in interstitial cells (data not shown), indicating that SM22α-positive cells in the interstitium might be myofibroblasts. On the other hand, SM22α-positive podocytes were never costained with αSMA.

However, the functional significance of SM22α in kidney diseases should be further investigated so that the pathophysiology, or the mechanism of the development, of the diseases can be better understood. Moreover, revealing the functional role of this molecule might lead to the therapeutic application for renal diseases by controlling its function.
Acknowledgements

The authors thank Mr. Masaki Nomata and Mr. Naofumi Imai for their skillful technique and helpful discussion. This study was supported by a grant-in-aid of Japanese for Scientific Research (No. 22590882 to M.S.) from the Ministry of Education, Culture, Sports, Science and Technology of Japan, and also by a grant for Promotion of Niigata University Research Projects.

Disclosure Statement

The authors have no conflicts of interest to disclose.

References

6. Lawson D, Harrison M, Shapland C: Fibroblast transgelin and smooth muscle SM22 are the same protein, the expression of which is down-regulated in many cell lines. Cell Motil Cytoskeleton 1997; 38:250–257.
26. Shirato I, Sakai T, Kimura K, Tomino Y, Kriz W: Cytoskeletal changes in podocytes associated with foot process effacement in Madu-